Nicola Groth

70 Rue Saint Jean De Dieu
Lyon, 69007, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate vaccine.

Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate vaccine.

Journal: The Journal of infectious diseases

Published: May 12, 2026

Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix® Tetra, a Seasonal Hemagglutinin-Based Vaccine.

Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix® Tetra, a Seasonal Hemagglutinin-Based Vaccine.

Journal: Vaccines

Published: April 21, 2025

Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.

Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.

Journal: Vaccines

Published: November 20, 2024

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

Journal: Human vaccines & immunotherapeutics

Published: April 16, 2014

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.

Journal: Journal of infection in developing countries

Published: December 19, 2013

Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.

Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.

Journal: American journal of epidemiology

Published: July 19, 2013

Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.

Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.

Journal: American journal of epidemiology

Published: September 04, 2012

Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.

Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.

Journal: Viral immunology

Published: June 14, 2012

A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.

A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.

Journal: Vaccine

Published: May 23, 2012

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

Journal: Human vaccines & immunotherapeutics

Published: March 20, 2012

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons.

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons.

Journal: Human vaccines & immunotherapeutics

Published: March 16, 2012

An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one.

An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one.

Journal: Vaccine

Published: March 06, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026